The lancet oncology
-
The lancet oncology · Jul 2022
Induction-maintenance approach for the chronic phase of chronic myeloid leukaemia (IMPACT-I): a prospective, single-arm, phase 2 study.
Imatinib and second-generation tyrosine-kinase inhibitors (2G-TKIs) are standard options for the first-line treatment of chronic myeloid leukaemia. Although 2G-TKIs are superior to imatinib in terms of rate and depth of molecular response, they do not bring significant improvements in survival outcomes, and concerns exist over their long-term safety. The availability of a generic formulation makes imatinib an attractive economical option. We propose a novel induction-maintenance approach that would have the advantage of inducing early molecular response with 2G-TKIs, followed by maintenance with the safer and more affordable imatinib. ⋯ 2017 Young Investigator Research Grant from the Hong Kong College of Physicians.
-
The lancet oncology · Jul 2022
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study.
Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018. The aim of the study was to evaluate the effect of IPC on the administration of chemotherapy or other treatments within the 14 days before death; multiple (more than one) emergency department visits within the 90 days before death; multiple (more than one) unplanned hospitalisations within the 90 days before death; and intensive care unit admission within the 90 days before death. ⋯ None.
-
The lancet oncology · Jul 2022
Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study.
In Colombia, all paid workers earning minimum wage or higher contribute part of their salary for access to the national health-care system through a type of insurance called contributive plan, which supports the remaining low-income population that is enrolled on the subsidised plan. During the COVID-19 pandemic, Colombia documented high mortality rate in patients with cancer, with higher mortality among low-income patients, according to data from our national registry of COVID-19 infection in patients with cancer. The aim of this research was to establish the differential access to COVID-19 vaccination depending on health insurance type, and its impact on mortality due to COVID-19 infection. ⋯ None.
-
The lancet oncology · Jul 2022
Comprehensive characterisation of Lynch syndrome and screening strategies: a cohort study of individuals at risk from Latin American genetic registries.
Systematic screening for Lynch syndrome is non-existent in most Latin American countries. Until regional guidelines are developed and implemented, patients with colorectal cancer in Latin America are being followed up according to international recommendations. The aim of this study was to characterise the current Lynch syndrome screening method in the region, and to explore the prevalence of Lynch syndrome in a large cohort of individuals at risk. ⋯ Norwegian Cancer Society (contract 194751-2017).
-
The lancet oncology · Jul 2022
Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid: a retrospective analysis.
Acute promyelocytic leukaemia (APL) results from the reciprocal chromosomal translocation t(15;17)(q24;21) (PML-RARA gene fusion). We have formulated an oral, economical, and outpatient-based preparation of arsenic trioxide and shown that it is efficacious for newly diagnosed and relapsed APL. In this study, we aimed to define the epidemiological landscape of APL in Hong Kong and to assess the effect of oral arsenic trioxide therapy on patient outcomes. ⋯ Health and Medical Research Fund of the Hong Kong Special Administrative Region, China (code 08191946).